- 专利标题: 14-3-3 targeting peptides for cancer treatment
-
申请号: US18076033申请日: 2022-12-06
-
公开(公告)号: US12122852B2公开(公告)日: 2024-10-22
- 发明人: Laura Hansen , Sandor Lovas , Nicholas Palermo
- 申请人: Creighton University , The Board of Regents of the University of Nebraska
- 申请人地址: US NE Omaha
- 专利权人: CREIGHTON UNIVERSITY,NUTECH VENTURES
- 当前专利权人: CREIGHTON UNIVERSITY,NUTECH VENTURES
- 当前专利权人地址: US NE Omaha; US NE Lincoln
- 代理机构: Advent, LLP
- 代理商 Mallory M. Henninger
- 分案原申请号: US16870253 2020.05.08
- 主分类号: C07K7/08
- IPC分类号: C07K7/08 ; A61K9/06 ; A61K9/107 ; A61K38/00 ; A61P35/00 ; C07K5/117
摘要:
Systems and methods for treatment of squamous cell carcinoma or other cancer utilizing targeting peptides are described. The targeting peptides interact with SCC cells or other cancerous cells to block or interfere with 14-3-3ε heterodimerization or CDC25A binding to 14-3-3ε. A peptide composition embodiment includes, but is not limited to, at least one of a first targeting peptide comprising a structure of Trp-Tyr-Trp-Lys-NH2 (SEQ ID NO: 1), a second targeting peptide comprising a structure of phospho-Ser178; Ac-Thr-Gln-Arg-Gln-Asn-Ser-(PO32−)-Ala-Pro-Arg-Met-Leu-Ser-Ser-Asn-NH2 (SEQ ID NO: 2), and a third targeting peptide comprising a structure of phospho-Thr507 residue; Ac-Arg-Thr-Lys-Ser-Arg-Thr(PO32−)-Trp-Ala-Gly-Glu-Lys-Ser-Lys-Arg-NH2 (SEQ ID NO: 3).
公开/授权文献
- US20230312645A1 14-3-3 TARGETING PEPTIDES FOR CANCER TREATMENT 公开/授权日:2023-10-05
信息查询